Suppr超能文献

血浆中组织型纤溶酶原激活物的快速作用抑制剂也是尿激酶的主要血浆抑制剂。

The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.

作者信息

Kruithof E K, Tran-Thang C, Bachmann F

出版信息

Thromb Haemost. 1986 Feb 28;55(1):65-9.

PMID:3085266
Abstract

We have compared the ability of a plasminogen activator inhibitor (PA-inhibitor) in human plasma, to form complexes with radioiodinated tissue-type plasminogen activator (t-PA) and high molecular weight urokinase (HMr-UK). Addition of 125I-t-PA (final concentration 10 IU/ml) or of 125I-HMr-UK (2 IU/ml) to a plasma containing 33 U/ml of PA-inhibitor resulted in the rapid formation of a 110,000 Mr complex of 125I-t-PA or a 95,000 Mr complex of 125I-HMr-UK with PA-inhibitor. Upon prolonged incubation of the plasma with 125I-HMr-UK a secondary complex of a Mr of 88,000 was observed, which probably derives from limited degradation of the 95,000 complex. Preincubation of the plasma with unlabelled t-PA, HMr-UK or LMr-UK at higher concentrations prevented the subsequent formation of complexes between radiolabelled PAs and the PA-inhibitor. These results thus demonstrate that t-PA and UK form complexes with the same PA-inhibitor. The rate of complex formation of 125I-t-PA or of 125I-HMr-UK with the plasma PA-inhibitor was similar (second order rate constant of association with PA-inhibitor in the order of 10(7) M-1s-1).

摘要

我们比较了人血浆中纤溶酶原激活物抑制剂(PA抑制剂)与放射性碘化组织型纤溶酶原激活物(t-PA)和高分子量尿激酶(HMr-UK)形成复合物的能力。向含有33U/ml PA抑制剂的血浆中加入125I-t-PA(终浓度10IU/ml)或125I-HMr-UK(2IU/ml),会迅速形成125I-t-PA与PA抑制剂的110,000Mr复合物或125I-HMr-UK与PA抑制剂的95,000Mr复合物。血浆与125I-HMr-UK长时间孵育后,观察到一种分子量为88,000的二级复合物,它可能源自95,000复合物的有限降解。用较高浓度的未标记t-PA、HMr-UK或低分子量尿激酶(LMr-UK)对血浆进行预孵育,可防止随后放射性标记的纤溶酶原激活物(PAs)与PA抑制剂之间形成复合物。因此,这些结果表明t-PA和尿激酶与同一种PA抑制剂形成复合物。125I-t-PA或125I-HMr-UK与血浆PA抑制剂的复合物形成速率相似(与PA抑制剂结合的二级速率常数约为10(7)M-1s-1)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验